Among lung neuroendocrine tumours (Lung-NETs), typical carcinoid (TC) and atypical carcinoid (AC) are considered separate entities as opposed to large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). By means of twoway clustering analysis of previously reported next-generation sequencing data on 148 surgically resected Lung-NETs, six histology-independent clusters (C1 → C6) accounting for 68% of tumours were identified. Low-grade Lung-NETs were likely to evolve into high-grade tumours following two smoke-related paths. Tumour composition of the first path (C5 → C1 → C6) was coherent with the hypothesis of an evolution of TC to LCNEC, even with a conversion of SCLC-featuring tumours to LCNEC. The second path (C4 → C2-C3) had a tumour composition supporting the evolution of AC to SCLC-featuring tumours. The relevant Ki-67 labelling index varied accordingly, with median values being 5%, 9% and 50% in the cluster sequence C5 → C1 → C6, 12% in cluster C4 and 50-60% in cluster C2-C3. This proof-of-concept study suggests an innovative view on the progression of pre-existing TC or AC to high-grade NE carcinomas in most Lung-NET instances.
Introduction
Lung neuroendocrine tumours (Lung-NETs) are currently divided into four histologic variants according to necrosis amount, number of mitoses per 2 mm 2 and a wide constellation of cytological, histological and immunohistochemical traits [1, 2] . They include typical carcinoid (TC), atypical carcinoid (AC), large-cell neuroendocrine carcinoma (LCNEC) and small-cell carcinoma (SCC) [1, 2] . This pathologic classification fits with a three-tier clinical scheme, according to which TC behave as low-grade malignant tumours, AC as intermediate-grade malignant tumours and the group of LCNEC and SCLC as high-grade malignant tumours with no significant survival differences [1, 2] .
The current believes support the notion that TC and AC make up different and separate tumour entities as opposed to LCNEC and SCLC [1, [3] [4] [5] [6] [7] [8] [9] [10] . Nonetheless, carcinoids and NE carcinomas of different organs may share several genetic alterations, yet with different prevalence rates, which push an unexpected concept of secondary evolution to be hypothesised in NETs [7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . This bewildering situation, which does not comply with the current classification scheme [1] , has been giving a variety of terms, such as (i) high-grade NE carcinoma with carcinoid morphology [21] , (ii) secondary high-grade NET [11] , (iii) well-differentiated NET with a morphologically apparent high-grade component [13] , (iv) transformed or mixed grade NET [13] , (v) well-differentiated NET with high-grade (G3) progression [22] , (vi) carcinoid-like LCNEC with MEN1 mutation [8, 23] , (vii) carcinoid or NET with proliferation rate progression at metastatic sites [24, 25] , (viii) progression of pulmonary carcinoid tumours [17] [18] [19] [20] , (ix) NE carcinoma with combined features ranging from well-differentiated (carcinoid) to small cell carcinoma [26] and (x) also the recently introduced category of G3 NET [27, 28] . The relative scarce knowledge on Lung-NET biology certainly limits our comprehension regarding the real origin of these tumour subtypes, which have been rather considered exceptions or outliers to the current pathogenesis models of separate tumour derivation [1, 28] . However, there is also the possibility for carcinoids to progress towards high-grade NETs as a result of either the natural history of the disease or the pressure of therapies [11] . This would represent an alternative view underlying the development of NETs arising anywhere in the body [29] [30] [31] . It is worth mentioning that these secondary NETs show a better prognosis and a different clinical presentation in comparison with de novo or primary highgrade NETs [11, 13] and that they may share common molecular traits and cancer drivers with carcinoids [11, 13, 14, 16, 32] .
We herein provide a molecular classification of a large cohort of 148 Lung-NETs comprising all histologic variants. Our findings support the hypothesis that aggressive LungNETs could evolve from different histologic subtypes after crucial gene alterations have been acquired during tumour progression.
Materials and methods

Patients and tumours
This study comprises a cohort of 148 Lung-NETs belonging to all histologic variants, which had previously been investigated by next-generation sequencing (NGS) [12] . Four Italian centres devoted to the diagnosis and care of Lung-NET patients (Turin, Genoa, Pisa, Verona) had participated in the current investigation [12] . Gene alteration results, including either mutations or copy number variations (CNVs), have been analysed to test the hypothesis of secondary Lung-NETs developing from pre-existing carcinoids. The cohort comprises 53 TC, 35 AC, 27 LCNEC and 33 SCLC according to the current World Health Organization (WHO) 2015 classification [1, 2] , all surgically treated and with no neoadjuvant treatments. The original material had been assayed in a discovery set by whole exome sequencing and high-coverage targeted sequencing and then validated by either customised or commercially available multigene panels for recurrent mutations and CNVs [12] . Paraffin tumour specimens had also been assessed by immunohistochemistry (IHC) for the expression of Ki-67 antigen [12] .
Ethics
As this study deals with reanalysis of previously generated and authorised molecular data by local ethics committees [12] , no further ethics release is necessary.
Study design
This is an in silico study generating a proof of concept concerning an innovative concept on secondary LungNETs developing through sequential gene alterations accounting for mutations and CNVs. We previously generated a list of 89 recurrently altered genes in Lung-NETs [12] , from which 40 unbiased recurrent gene alterations present in at least three different tumours were abstracted to guarantee specificity to molecular findings by minimising the role of hitchhiking gene alterations. This 40-gene signature included mutations in 27 genes and CNVs in 13 genes. The 27 genes harbouring recurrent mutations were ARID1A, ARID1B, ARID2, ATM, CSMD3, DSCAML1, ERBB4, KMT2C/MLL3, KMT2D/MLL2, KRAS, LRP1B, MEN1, NCAM2, NOTCH2, PBRM1, PCLO, PIK3CA, PTPRZ1, RB1, SETD2, SMARCA2, SMARCA4, SPHKAP, STK11, THSD7B, TP53, TSC2. The 13 genes tested for CNVs were BCL2, FGFR1, MEN1, MYC, MYCL, PIK3CA, RICTOR, RB1, SDHA, SMAD4, SRC, TERT and TP53, as previously detailed [12] . Such a 40-gene signature was thus used for tumour analysis by clustering evaluation.
Statistical analysis
Hierarchical clustering analysis was performed using Cluster 3.0 software (http://bonsai.hgc.jp/~mdehoon/ software/cluster/software.htm) and JAVA treeview (http://jtreeview.sourceforge.net) on categorised data. This categorization ranked 0 for wild-type (WT) configuration, 1 for mutation or loss of heterozygosity (LOH) or low gain (3-5 copies) and 2 for deletion or high gain (> 5 copies), as also explained in the Fig. 1a legend. Clustering metrics used were Spearman rank correlation and average linkage. Frequencies of genetic alteration were calculated by averaging the number of altered samples in each cluster. Hierarchical clustering analysis of frequencies was done using un-centred correlation and average linkage. Clusters were constructed taking into account correlation coefficients greater than 0.2. Bar plots and radar plots were prepared using Excel 2015 (Microsoft). Kaplan-Meier plots and log-rank statistical analysis was performed using JMP 12 (SAS). Univariate and multivariate analysis was performed using the SAS statistical software, version 9.2 (SAS Institute, Inc., Cary, NC). Categorical variables were compared by KruskalWallis test, Fisher exact t test or chi-squared test (also using the Monte Carlo simulation) as appropriate. All p values were two-sided, and p values < 0.05 were considered as significant. Fig. 1 a-c Molecular analysis of Lung-NETs. a Unsupervised hierarchical cluster analysis of the 40-gene alterations identified in the 148 sample cohort. Six clusters were identified, named C1 → C6, and accounted for 100 out of 148 tumour samples. Types of genetic alterations are explained by using different colours, as per the legend. "Amp" stands for amplification/gain, "del" for deletion/loss, "mut" for mutation, "LOH" for loss of heterozygosity and "Homo" for homozygous deletion. Low and high amplification/gain was defined by the cut-off threshold of 5 as previously detailed (see reference #12). The signature included 27 gene mutations (ARID1A, ARID1B, ARID2, ATM, CSMD3, DSCAML1, ERBB4, KMT2C/MLL3, KMT2D/MLL2, KRAS, LRP1B, MEN1, NCAM2, NOTCH2, PBRM1, PCLO, PIK3CA, PTPRZ1, RB1, SETD2, SMARCA2, SMARCA4, SPHKAP, STK11, THSD7B, TP53, TSC2) and 13 copy number variations (BCL2, FGFR1, MEN1, MYC, MYCL, PIK3CA, RICTOR, RB1, SDHA, SMAD4, SRC, TERT, TP53). Further details can be found in the reference #12. b Radar plot of prevalent genetic alterations (frequency > 0.5, i.e. 50%) in the clusters identified in Fig. 1a . Numbers identify the percentages of the relevant gene alterations. c Hierarchical cluster analysis of frequencies of all genetic alterations found in C1 → C6 clusters. Only prevalent genetic alterations (frequency > 0.5) are shown
Results
Hierarchical clustering analysis reveals distinct groups of tumours
We initially performed supervised clustering analysis to evaluate the distribution of gene alterations across our cohort of 148 Lung-NETs according to histologic subtyping. One-way clustering analysis confirmed that TC showed the lowest burden of gene alterations, while AC, LCNEC and SCLC progressively accumulated gene mutations and CNVs (Supplemental Fig. 1A and Supplemental Table 1 ). The clinicopathologic characteristics of the tumour series according to histologic subtyping are reported in Supplemental Table 2 . Survival curves confirmed an excellent prognosis for TC, an intermediate prognosis for AC and a progressively deteriorated clinical course for LCNEC and SCLC (Supplemental Fig. 1B) .
We next performed unsupervised clustering analysis using the same 40-gene set. This analysis uncovered six distinct clusters with correlation coefficients greater than 0.2 (see "Materials and methods" section), named C1 → C6, which showed different patterns of gene alterations, either mutations or CNVs (Fig. 1a) , suggesting the existence of molecular subtypes which included different histologic subtypes. These clusters accounted for 100 (68%) of the 148 Lung-NETs, while the remaining unclassifiable tumours were descriptively labelled as "others". The C1 → C6 clusters were characterised by one or more gene alterations with a prevalence higher than 0.5 (i.e. 50% of samples) in the relevant tumour clusters (Fig. 1b) . They included (i) RB1 deletion (RB1-del) in cluster C1; (ii) TP53 mutation and deletion (TP53-mut and TP53-del), RICTOR/ SDHA/TERT copy number gains (RICTOR gain, SDHA gain and TERT gain) in cluster C2; (iii) TP53 mutation (TP53-mut) and RICTOR copy number gain (RICTOR gain) in cluster C3; (iv) TERT and SDHA gain (TERT gain and SDHA gain) in cluster C4; (v) TP53 deletion (TP53-del) and MYC gain (MYC gain) in cluster C5; and (vi) KRAS/TP53 mutation (KRAS-mut and TP53-mut) and MYCL copy number gain (MYCL gain) in cluster C6 (Fig. 1b) .
To further investigate the relationship among C1 → C6 clusters, we extended unsupervised clustering analysis considering the prevalence of alterations in each cluster of all genes analysed (N = 40) (Fig. 1c) . Notably, C5 cluster closely resembled cluster C1 (Fig. 1c) for sharing TP53/RB1/MEN1 gene deletion along with MYC and PIK3CA gains (Fig. 2a) . In turn, C6 cluster was similar to C1 for MEN1/RB1/TP53 deletion, KMTD2/TP53 mutation and MYC gain (Fig. 2a, upper middle  part) . Furthermore, C4 cluster shared with C6 MYC/MYCL/ RICTOR gains, RB1/TP53 deletion and MEN1/KMT2D-MLL2/TP53 mutation (Fig. 2a , upper right part) while KRAS mutation was private to cluster C6 (Fig. 2a) . Finally, C3 cluster showed an expansion of RICTOR gain and TP53 mutation (Fig. 2a, lower left part) which was maintained in C2 cluster like all other genetic alterations identified, whereas MEN1 deletion was private to C4 cluster. However, C2 cluster was further characterised by an evident expansion of RB1/TP53 deletion, TERT/SDHA gains and, marginally, LRP1B mutation (Fig. 2a, lower right part) . Therefore, most tumours have a similar mutational pattern in the identified clusters despite different histologic appearance (Fig. 2b) , which suggests a common evolutionary relationship. Interestingly, the median Ki-67 LI was 5%, 9% and 50% in clusters C5, C1 and C6 and 12% and 50-60% in clusters C4 and C2-C3, respectively (Table 1) . Furthermore, Ki-67 immunopositivity was heterogeneously distributed in neoplastic cells at the level of individual high-grade tumours (Supplemental Fig. 2 ).
Univariate and multivariate analysis
Clusters differed statistically for gender, smoking status, histological subtyping and Ki-67 positivity, but not for age of patients and tumour stage (Table 1) . Of note, a large prevalence of carcinoids (26/31 tumours, 84%) but with inverted frequency was observed in cluster C5 (9 TC and 3 AC out of 14 tumours) and C4 (2 TC and 12 AC out of 17 tumours), whereas the opposite held true for high-grade Lung-NETs (27/35 tumours, 77%), which prevailed in cluster C3 (6 LCNEC and 4 SCLC out of 15 tumours) and cluster C2 (4 LCNEC and 13 SCLC out of 20 tumours) ( Fig. 2b ; Table 1 ). Lack of SCLC was notable in cluster C6 where there was a slight prevalence of LCNEC (4/7 tumours) over TC and AC ( Fig. 2b; Table 1 ), while AC was virtually absent in cluster C1 in front of prevalent TC, SCLC and LCNEC ( Fig. 2b; Table 1 ). Tumours not in C1 → C6 clusters were 48 and included mostly carcinoids (39/48 cases, 81%), especially TC (26 cases), while high-grade NETs (4 LCNEC and 5 SCLC) were negligible (Fig. 2b, Table 1 ).
Cox univariate analysis showed that age, male gender, smoking habit, tumour stage, histologic subtyping and clusters affected survival (Table 2 ). Multivariate analysis confirmed that age, histological subtyping (SCLC), tumour stage (III-IV) and C3 cluster affected survival, independently of other clinicopathologic parameters ( Table 2 ).
Discussion
Our results are likely to support a paradigm shift to the current view of the pathogenesis of Lung-NETs by suggesting that TC has a potential to evolve in high-grade tumours, either directly or through intermediate steps, resembling the more aggressive LCNEC and SCLC subtypes in terms of acquired molecular alterations. These findings confirm the concept of secondary NETs we recently authorised in NETs arising in the thymus [11] . A plethora of different terms has been used in NET literature to describe these secondary tumours arising in different organs [8, 11, 13, 17-21, 23-26, 33, 34] . The recently suggested category of NET G3 in the gastrointestinal tract [6, 27] , which has been now introduced in the 2017 WHO classification of endocrine tumours [28] , may well represent secondary NETs arising from pre-existing G1/G2 NETs. It is tempting to hypothesise that this peculiar phenomenon is inherent to NETs at different sites and not so rare as currently believed [17] [18] [19] [20] . We herein provide molecular suggestion that most Lung-NETs may indeed belong to this category, possibly as not unpredictable exceptions or bewildering outliers stochastically crossing the spectrum of NETs [1, [3] [4] [5] [6] [7] [8] [9] , but rather a systematic biologic phenomenon, thus realising an innovative view in the development of Lung-NETs.
Our starting observation was that carcinoids and NE carcinomas in different organs may share several genetic abnormalities, yet with different prevalence rates, such as mutations, CNVs and microRNA expression levels [7, [11] [12] [13] [14] [15] [16] . This was at variance with what we observed upon supervised analysis of molecular alterations in our tumour series or others documented in NE neoplasms of the pancreas [35] when using morphology as the only discriminating tool, where TC/AC vs. LCNEC/SCLC and NET-G3 vs. NEC-G3 were compared, respectively. In other words, morphology alone would not be the optimal approach to identify this phenomenon due to lower accuracy, while Ki-67 LI distribution evaluation would be of greater value. Moreover, the existence of patient subsets with different life expectation in each histologic variant of Lung-NETs is in keeping with an evolution concept within the clinicopathologic spectrum of these tumours [17] [18] [19] [20] 36] . In this scenario, we underwent an in silico unsupervised analysis on previously published molecular data of Lung-NETs [12] , which confirmed the existence of distinct clusters of tumours with a heterogeneous composition of histologic subtypes showing several common genomic abnormalities. Additional sources for validation, such as Cancer Genome Atlas (https://cancergenome.nih.gov) or NGS studies on carcinoids [3] , LCNEC [8, 9] or SCLC [4] , were discharged due to lack of comparable information on histologic subtypes, survival or mutation/CNV details.
Our study provides new molecular evidence to the existence and prevalence of secondary NETs in the lung. These tumours, which have not been comprised in the 2015 WHO classification [1, 2] , share molecular alterations indicative of a common origin with additional gene alterations likely occurring over time, which would be instrumental to the development of high-grade tumours [11] . The opposite situation, i.e. the downgrading of poorly differentiated NETs, is contradicted by the additional gene aberrations occurring in high-grade elements [11] and the generally less aggressive clinical behaviour attributed to these tumours [11, 13, 25] . Of note, secondary-type evolution would not be confined to NETs, but can be observed in glioblastoma evolving from long-standing astrocytoma [37, 38] or triple negative breast cancer stemming from adenoid cystic carcinoma [39] .
As morphology alone may be deceptive and inconclusive, the existence of secondary NETs has been questioned, with only single case reports or small tumour series being described in NET literature [8, 11, 13, 17-21, 23-26, 33, 34] . We herein provide the first molecular support to the contention that secondary NETs are under-recognised entities in the lung inasmuch as they would represent the majority (in our hands, 68%) of tumours arising in this organ. It is worth noting that in many Lung-NET series, about 20-30% of high-grade tumours fulfilling criteria for either SCLC or LCNEC showed long survival or presented with organoid NE architecture featuring trabeculae, ribbons and palisading aggregates [36, [40] [41] [42] [43] . This observation could imply that high-grade NETs investigated on surgical specimens (including many of those thus far published in NGS studies) could represent secondary tumours according to our prevalence rate results compared to homologous tumours presenting at onset with metastatic disease and thus unsuitable for surgical resection. The uneven distribution of Ki-67 immunostaining within tumours, as highlighted by the differential distribution of Ki-67 among clusters we documented also at the level of individual tumours, could help to better highlight double components of low-and high-grade cells within secondary NETs, as demonstrated in the thymus [11] and the pancreas [13] .
In our study, six clusters were identified according to unsupervised analysis, with the diverse tumour subtypes differentially distributed among them as a function of different evolution lines not predicted upon morphology grounds. On the basis of the clustering tree organization, two evolutionary-related groups could be identified: C5 → C1 → C6 and C4 → C2-C3. The first group showed differential inactivation of tumour suppressor genes upon deletion or mutation alongside with MYC copy number gains and private KRAS mutation limited to cluster C6 in a clinical setting of predominantly male patients with smoking habit. The different tumour composition of these clusters would be coherent with the hypothesis of an evolution of TC to LCNEC, even with a conversion of some SCLC-featuring tumours to LCNEC. The recently described categories of carcinoids with proliferation rate progression at metastatic sites [24] , carcinoid-like LCNEC [8, 11] , NSCLC-like LCNEC harbouring KRAS mutation [8, 9] and the well-known low diagnostic reproducibility of LCNEC diagnosis towards either AC or SCLC [44, 45] support all our observations. The second group showed differential copy number gains at several genes (TERT, SDHA, MYCL, RICTOR) alongside TP53 inactivation upon deletion or mutation and RB1 deletion, with private MEN1 deletion in C4 where AC prevailed [17] , in a clinical setting of predominantly male patients with smoking habit. The tumour composition of these clusters would be in keeping with the evolution of AC to SCLC-featuring tumours or SCLC-like LCNEC as described by others [8] . Interestingly, the Ki-67 immunostaining varied accordingly in a significant way, with median values being 5-9% in clusters C1-C5 and 50-60% in clusters C2-C3. All these observations indicated that some TC or AC harbouring a particular combination of smoke-related genetic alterations and/or male gender had the potential to give rise to high-grade LungNETs. The description of metastatic pulmonary carcinoid tumours [24] or pancreatic NETs [6, 25] showing proliferation rate progression at metastatic sites and featuring SCLC-like [24] or NET G3-like [25] appearance are in keeping with our results.
Another interesting observation regarded the intra-tumour heterogeneity of our 40-gene signature in Lung-NETs, which displayed different alterations in single tumours entering the diverse clusters (Fig. 1a) , thus reinforcing once again the concept of secondary tumours in transition because of several gene alterations accumulated over time.
Forty-eight out of 148 Lung-NETs we examined in the current study did not enter any clustering: interestingly, there was in these tumours a clear prevalence of carcinoids and women patients, which supported on also clinical grounds the existence of secondary tumours arising in a different set of patients. Despite limitations to our study principally due to its retrospective character and limited number of tumours, which precluded an independent validation of our findings, we identified a histology-independent clustering of molecular data by others [8] , in keeping with our results. This cohort of LCNEC, which had originally been classified as NSCLC-like LCNEC and SCLC-like LCNEC according to targeted NGS profiling, was indeed reclustered into three different groups where histology was inconsistently associated with molecular subtyping (Supplemental Fig. 3 ). Recent data on primary and secondary SCLC and LCNEC developing from NSCLC with NE differentiation according to somewhat similar molecular alterations [33] further confirm our observations. Therefore, these secondary NETs, while realising a paradigm shift to the current pathogenesis, may be an integral but under-recognised part of the natural history of NETs, either spontaneous [11] or resulting from therapy pressure [46] .
Conclusion
We identified widely shared genetic alterations in the majority of Lung-NETS organised in a hierarchical structure comprising six main clusters. This supports a concept of evolution of carcinoids towards high-grade tumours. The clinical implications and the precise molecular mechanisms of these secondary Lung-NETs will have to be deepened in the near future by additional studies, also including in vivo and in vitro experimental models.
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